Health Care [ 8/12 ] | Biotechnology [ 34/74 ]
NASDAQ | Common Stock
SpringWorks Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for underserved patient populations suffering from rare diseases and cancer.
It offers OGSIVEO (nirogacestat), an oral small molecule gamma secretase inhibitor for the treatment of desmoid tumors; and GOMEKLI (mirdametinib), an oral small molecule inhibitor of MEK1 and MEK2 for the treatment of adult and pediatric patients two years of age and older with neurofibromatosis type 1-associated plexiform neurofibromas (NF1-PN).
The company also develops Nirogacestat, is also in Phase 2 clinical development as a monotherapy for the treatment of ovarian granulosa cell tumors (GCT), a subtype of ovarian cancer; and mirdametinib for the treatment of solid tumors harboring other MAPK aberrations, including for the treatment of pediatric and young adult patients with low-grade gliomas that is in Phase 1/2 clinical trial.
In addition, its products under development include Brimarafenib (BGB-3245), an oral selective small molecule inhibitor of monomeric and dimeric forms of activating BRAF mutations.
The company has license agreements with Pfizer Inc. for nirogacestat and mirdametinib; and Katholieke Universiteit Leuven and the Flanders Institute for Biotechnology for a portfolio of novel small molecule inhibitors of the TEA Domain.
SpringWorks Therapeutics, Inc. was founded in 2017 and is headquartered in Stamford, Connecticut.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Feb 25, 25 | -1.04 Increased by +28.28% | -0.71 Decreased by -45.96% |
| Nov 12, 24 | -0.72 Increased by +43.24% | -0.75 Increased by +3.89% |
| Aug 7, 24 | -0.54 Increased by +56.80% | -1.11 Increased by +51.35% |
| May 2, 24 | -1.18 Increased by 0.00% | -1.17 Decreased by -0.85% |
| Feb 27, 24 | -1.45 Decreased by -23.93% | -1.24 Decreased by -16.94% |
| Nov 2, 23 | -1.27 Increased by +7.30% | -1.33 Increased by +4.51% |
| Aug 2, 23 | -1.25 Increased by +11.35% | -1.26 Increased by +0.79% |
| May 3, 23 | -1.18 Increased by +6.35% | -1.25 Increased by +5.60% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Dec 31, 24 | 61.55 M Increased by +1.03 K% | -77.30 M Increased by +18.05% | Decreased by -125.59% Increased by +92.75% |
| Sep 30, 24 | 49.30 M Increased by +782.58% | -53.53 M Increased by +32.61% | Decreased by -108.58% Increased by +92.36% |
| Jun 30, 24 | 59.73 M Increased by +924.93% | -39.92 M Increased by +48.77% | Decreased by -66.83% Increased by +95.00% |
| Mar 31, 24 | 21.01 M Increased by +278.01% | -87.39 M Decreased by -26.39% | Decreased by -416.00% Increased by +66.57% |
| Dec 31, 23 | 5.45 M Decreased by -6.07% | -94.32 M Decreased by -34.93% | Decreased by -1.73 K% Decreased by -43.65% |
| Sep 30, 23 | 5.59 M Increased by +566.59% | -79.44 M Decreased by -11.14% | Decreased by -1.42 K% Increased by +83.33% |
| Jun 30, 23 | 5.83 M Increased by +1.57 K% | -77.92 M Decreased by -12.85% | Decreased by -1.34 K% Increased by +93.26% |
| Mar 31, 23 | 5.56 M Increased by +111.04 K% | -69.14 M Decreased by -11.88% | Decreased by -1.24 K% Increased by +99.90% |